← Leaderboards
Pinghui Feng
Harvard University (Medical School)
$20,425,150
Attributed
$22,349,003
Total exposure
18
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$22,349,003 · 18
By mechanism
R01$13,791,857 · 7
RF1$3,354,022 · 1
R35$3,066,007 · 1
R21$1,991,325 · 5
P51$140,792 · 3
R13$5,000 · 1
Top collaborators
- Chao Zhang5 shared
- Chengyu Liang2 shared
Others in their field
Top investigators on “Herpesviridae”
- David Heimbrook · Leidos Biomedical Research, Inc.$56,561,099
- Jae U Jung · Cleveland Clinic Lerner Com-Cwru$31,272,078
- Scott W Wong · Oregon Health And Science University$27,573,756
- Shou-Jiang Gao · University Of Texas Hlth Science Center$21,464,409
- Shlomo Shinnar · Montefiore Medical Center (Bronx, Ny)$20,780,078
- Louis J. Picker · Oregon Health And Science University$19,181,483
Research focus
HerpesviridaeProteinsViralMolecularMediatingCellsHerpesviridae InfectionsHuman Herpesvirus 8InfectionImmunePathogenInsightDeamidationImmune ResponseMalignant NeoplasmsVirus Host InteractionLytic ReplicationVirusPathway InteractionsGammaherpesvirusVirus DiseasesKaposi SarcomaHuman Herpesvirus 4Mouse Model
Grant awards (49)
Regulated cGAS activation in HSV-1-associated neuropathogenesis.$3,354,022
RF1 · FY2025 · AG · contact PI
Explore a key nucleotide synthesis enzyme to develop a broad-spectrum antiviral therapy.$831,235
R01 · FY2025 · AI · contact PI
Explore roles of HSV-1 in Alzheimer's disease using mouse models$760,469
R01 · FY2025 · AG · contact PI
Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma$379,725
R01 · FY2025 · CA · contact PI
Targeting the UL37 deamidase to impede HSV-1 infection.$201,275
R21 · FY2025 · AI · contact PI
Explore roles of HSV-1 in Alzheimer's disease using mouse models$788,360
R01 · FY2024 · AG · contact PI
Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma$379,725
R01 · FY2024 · CA · contact PI
Targeting the UL37 deamidase to impede HSV-1 infection.$248,875
R21 · FY2024 · AI · contact PI
Explore roles of HSV-1 in Alzheimer's disease using mouse models$798,989
R01 · FY2023 · AG · contact PI
Targeting IKKepsilon-mediated nucleotide synthesis in KSHV-associated lymphoma$378,581
R01 · FY2023 · CA · contact PI
Explore roles of HSV-1 in Alzheimer's disease using mouse models$798,803
R01 · FY2022 · AG · contact PI
NFAT activation in kGPCR tumorigenesis$377,438
R01 · FY2021 · CA · contact PI
NFAT activation in kGPCR tumorigenesis$377,438
R01 · FY2020 · CA · contact PI
Targeting the host NDP kinase to abrogate viral dissemination$62,715
R21 · FY2020 · DE
Exploring roles of protein deamidation in oral inflammation$1,042,335
R35 · FY2019 · DE · contact PI
Targeting an immune kinase to purge KSHV latent infection$676,564
R01 · FY2019 · DE · contact PI
NFAT activation in kGPCR tumorigenesis$366,114
R01 · FY2019 · CA · contact PI
Targeting the host NDP kinase to abrogate viral dissemination$247,500
R21 · FY2019 · DE
Exploring roles of protein deamidation in oral inflammation$1,059,247
R35 · FY2018 · DE · contact PI
Targeting an immune kinase to purge KSHV latent infection$676,564
R01 · FY2018 · DE · contact PI
NFAT activation in kGPCR tumorigenesis$377,438
R01 · FY2018 · CA · contact PI
Exploring roles of protein deamidation in oral inflammation$287,186
R35 · FY2018 · DE · contact PI
Regulated MAVS-mediated signaling in KSHV lytic replication$206,250
R21 · FY2018 · AI · contact PI
Exploring roles of protein deamidation in oral inflammation$677,239
R35 · FY2017 · DE · contact PI
Targeting an immune kinase to purge KSHV latent infection$676,564
R01 · FY2017 · DE · contact PI
Protein Deamidation in Innate Immune Evasion Regulated by Viral Pseudo Enzymes$454,814
R01 · FY2017 · DE · contact PI
NFAT activation in kGPCR tumorigenesis$377,438
R01 · FY2017 · CA · contact PI
Regulated MAVS-mediated signaling in KSHV lytic replication$247,500
R21 · FY2017 · AI · contact PI
Targeting an immune kinase to purge KSHV latent infection$676,564
R01 · FY2016 · DE · contact PI
The 19th International Workshop on KSHV and Related Agents$5,000
R13 · FY2016 · CA · contact PI
Proviral Roles of an Innate Immune Pathway$412,500
R01 · FY2015 · DE · contact PI
A recombinant virus approach for gamma herpesvirus oncogenesis$205,885
R21 · FY2015 · AI · contact PI
Proviral Roles of an Innate Immune Pathway$411,250
R01 · FY2014 · DE · contact PI
A recombinant virus approach for gamma herpesvirus oncogenesis$246,313
R21 · FY2014 · AI · contact PI
Proviral Roles of an Innate Immune Pathway$393,600
R01 · FY2013 · DE · contact PI
Post-Translational Events Underlying the KSHV vGPCR Pathogenesis$310,286
R01 · FY2013 · CA · contact PI
Proviral Roles of an Innate Immune Pathway$410,000
R01 · FY2012 · DE · contact PI
Post-Translational Events Underlying the KSHV vGPCR Pathogenesis$329,756
R01 · FY2012 · CA · contact PI
Proviral Roles of an Innate Immune Pathway$407,500
R01 · FY2011 · DE · contact PI
Post-Translational Events Underlying the KSHV vGPCR Pathogenesis$224,008
R01 · FY2011 · CA · contact PI
Post-Translational Events Underlying the KSHV vGPCR Pathogenesis$100,411
R01 · FY2011 · CA · contact PI
Post-Translational Events Underlying the KSHV vGPCR Pathogenesis$325,775
R01 · FY2010 · CA · contact PI
Post-Translational Events Underlying the KSHV vGPCR Pathogenesis$313,948
R01 · FY2009 · CA · contact PI
INHIBITION OF MITOCHONDRION-DEPENDENT APOPTOSIS BY HERPESVIRAL PROTEIN$32,442
P51 · FY2008 · RR · contact PI
K7 regulates KSHV G protein-coupled receptor turnover$164,462
R21 · FY2007 · CA · contact PI
GAMMAHV68 VMAP MITOCHONDRIAL ANTI-APOPTOSIS PROTEIN$31,562
P51 · FY2007 · RR · contact PI
K7 regulates KSHV G protein-coupled receptor turnover$122,035
R21 · FY2006 · CA · contact PI
K7 regulates KSHV G protein-coupled receptor turnover$38,515
R21 · FY2006 · CA · contact PI
KSHV MITOCHONDRIAL K7 PROTEIN$76,788
P51 · FY2003 · RR